Palmitoyl-dl-carnitine chloride was used as a protein kinase C inhibitor to provide a cationic surface charge to LARPC. The formulation was characterized for particle size, zeta potential, drug release and various cell culture assays using HUVEC and vemurafenib resistant melanoma cells.
[Experimental Cell Research]
Fu, Y., Rathod, D., & Patel, K. (2020). Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma. Experimental Cell Research, 112275. https://doi.org/10.1016/j.yexcr.2020.112275 Cite
Graphical Abstract
Bookmark

No account yet? Register

0
Share
Share